# US 2026/0097079 A1 · Removal of endogenous tcr chains for enhanced tcr-based immunotherapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097079 A1
- Document ID: US20260097079A1
- Status: Published application
- Kind: A1
- Application number: 19/415,932
- Filed: 2025-12-11
- Published: 2026-04-09
- Earliest claimed: 2023-06-16
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Mohsen Khosravi MAHARLOOEI; Giorgia ZANETTI; Remi CREUSOT; Megan SYKES
- Web page: https://patentgrep.com/patent/US20260097079A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4272: {Melan-A/MART}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Methods and compositions for treating a disease in a subject comprising administering an adoptive cell therapy (ACT) to the subject, the ACT comprising delivering a modified lymphocyte comprising a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR); at least one inactivated endogenous TCRα chain allele; and at least one inactivated endogenous TCRβ chain allele.

## Claims

### Claim 1

A method of treating a disease in a subject comprising administering an adoptive cell therapy (ACT) to the subject, the ACT comprising delivering a modified lymphocyte comprising
i) a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR);
ii) at least one inactivated endogenous TCRα chain allele; and
iii) at least one inactivated endogenous TCRβ chain allele;
thereby treating the disease of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lymphocyte comprises a modified TCR, and the modified TCR comprises a TCRα chain expressed from an exogenous nucleotide coding sequence lacking introns and a TCRβ chain expressed from an exogenous nucleotide coding sequence lacking introns.

### Claim 3 (depends on 1)

The method of claim 1, wherein each endogenous TCRα chain allele is inactivated in the modified lymphocyte, preferably such that the inactivation knocks out each TCRα chain allele, preferably such that an endogenous, full-length and/or functional TCRα chain is not expressed by the modified lymphocyte.

### Claim 4 (depends on 1)

The method of claim 1, wherein each endogenous TCRβ chain allele is inactivated in the modified lymphocyte, preferably such that the inactivation knocks out each TCRβ chain allele, preferably such that an endogenous, full-length and/or functional TCRβ chain is not expressed by the modified lymphocyte.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRα chain allele is a T Cell Receptor Alpha Constant (TRAC) allele, preferably wherein each TRAC allele is inactivated in the modified lymphocyte.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRα chain allele is an inactivated endogenous TRAC allele comprising genetic modification within 50 nucleotides of a TRAC intron-exon boundary.

### Claim 7 (depends on 6)

The method of claim 6, wherein the TRAC intron-exon boundary is the boundary between (i) TRAC intron 1 and exon 1, (ii) TRAC exon 1 and intron 2, (iii) TRAC intron 2 and exon 2, (iv) TRAC exon 2 and intron 3, (v) TRAC intron 3 and exon 3, and/or (vi) TRAC exon 3 and intron 4, preferably between TRAC intron 1 and exon 1 and/or between TRAC exon 1 and intron 2.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRα chain allele comprises a genetic modification to a sequence comprising CAGGGTTCTGGATATCTGT (SEQ ID NO: 3), CTGCCCTTACCTGGGCT (SEQ ID NO: 4), CATCACAGGAACTTTCTAAA (SEQ ID NO: 5), AGCTTTGAAACAGGTAAGAC (SEQ ID NO: 6), TTCGTATCTGTAAAACCAAG (SEQ ID NO: 7), and/or TCAAGGCCCCTCACCTCAGC (SEQ ID NO: 8) located on a TRAC coding or template strand.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRβ chain allele is a T Cell Receptor Beta Constant 1 (TRBC1) allele or a T Cell Receptor Beta Constant 2 (TRBC2) allele, preferably wherein each TRBC1 allele and each TRBC2 allele is inactivated in the modified lymphocyte.

### Claim 10 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRβ chain allele is an inactivated endogenous TRBC1 allele and/or an inactivated endogenous TRBC2 allele comprising a genetic modification within 50 nucleotides of a TRBC1 intron-exon boundary and/or a TRBC2 intron-exon boundary.

### Claim 11 (depends on 10)

The method of claim 10, wherein the TRBC1 intron-exon boundary is the boundary between TRBC1 exon 1 and intron 2, and/or wherein the TRBC2 intron-exon boundary is the boundary between TRBC2 exon 1 and intron 2.

### Claim 12 (depends on 1)

The method of claim 1, wherein the inactivated endogenous TCRβ chain allele comprises a genetic modification to a sequence comprising CCTGGGGTAGAGCAGGTGAG (SEQ ID NO: 1) and/or CCACTCACCTGCTCTACCCC (SEQ ID NO: 2) located on a TRBC1 coding or template strand and/or a TRBC2 coding or template strand.

### Claim 13 (depends on 1)

The method of claim 1, wherein the modified T cell receptor is encoded by a codon-optimized nucleotide sequence or a non-codon-optimized nucleotide sequence.

### Claim 14 (depends on 1)

The method of claim 1, wherein a portion of the inactivated endogenous TCRα chain allele and/or inactivated endogenous TCRβ chain allele is excised, and/or comprises at least two genetic modifications.

### Claim 15 (depends on 1)

The method of claim 1, wherein the modified TCR is a transgenic TCR and/or an exogenously introduced TCR.

### Claim 16 (depends on 1)

The method of claim 1, wherein the modified TCR is exogenously introduced into the lymphocyte by transduction of a viral vector, preferably a lentiviral vector, or by delivery of a naked DNA molecule.

### Claim 17

A method of modifying a cell for adoptive cell therapy, the method comprising:
inactivating an endogenous TCRα chain allele and an endogenous TCRβ chain allele encoded by the cell, preferably by introducing at least one engineered nuclease to the cell,
thereby modifying the cell for adoptive cell therapy.

### Claim 18 (depends on 17)

The method of claim 17, wherein each endogenous TCRα chain allele is inactivated in the modified cell, preferably such that the inactivating knocks out each TCRα chain allele, preferably such that an endogenous, full-length and/or functional TCRα chain is not expressed by the cell and/or wherein each endogenous TCRβ chain allele is inactivated in the modified cell, preferably such that the inactivating knocks out each TCRβ chain allele, preferably such that an endogenous, full-length and/or functional TCRβ chain is not expressed by the cell.

### Claim 19

A mammalian immune cell modified by having a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR); at least one inactivated endogenous TCRα chain allele; and at least one inactivated endogenous TCRβ chain allele.

### Claim 20 (depends on 19)

A method for reducing the likelihood of a graft versus host disease associated with a TCR or CAR-T therapy for a pathology in a subject, comprising administering to the subject a modified lymphocyte of claim 19 comprising
i) a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR);
ii) at least one inactivated endogenous TCRα chain allele; and
iii) at least one inactivated endogenous TCRβ chain allele;
thereby treating the pathology in the subject and reducing the likelihood of a graft versus host disease in the subject.
or
a method for enhancing expression and/or formation of a therapeutic TCR in a cell modified for an adoptive cell therapy, the method comprising:
inactivating an endogenous TCRα chain allele and an endogenous TCRβ chain allele encoded by the cell, preferably by introducing at least one engineered nuclease to the cell and expressing the therapeutic TCR in the cell,
thereby enhancing expression and/or formation of a therapeutic TCR modifying the cell for adoptive cell therapy,
or
a method for enhancing the sensitivity of an adoptive cell therapy TCR to an antigen, comprising modifying a cell expressing the adoptive cell therapy TCR by inactivating an endogenous TCRα chain allele and an endogenous TCRβ chain allele encoded by the cell, preferably by introducing at least one engineered nuclease to the cell, thereby enhancing the sensitivity of the adoptive cell therapy TCR to an antigen relative to an otherwise identical cell expressing the adoptive cell therapy TCR but not modified to inactivate an endogenous TCRα chain allele and an endogenous TCRβ chain allele encoded by the cell.
